Clinical trial · Interventional
Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.
Efficacy of the Oncoxin-Viusid® Oral Solution in Reducing the Adverse Reactions of Chemotherapy and Radiotherapy in Patients Diagnosed With Cervical Cancer and Endometrial Adenocarcinoma.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy of oral solution Oncoxin-Viusid in the reduction of acute toxicity of Radiotherapy (RTP) and Chemotherapy (QTP) in patients with histological diagnosis of cervical cancer and endometrial adenocarcinoma. This is a phase II, prospective, randomized and double blind clinical trial, which will include 66 patients assigned to 2 treatment arms: 33 patients will receive conventional treatment, plus a placebo of the nutritional supplement and another 33 patients will receive along with the conventional treatment the Oncoxin-Viusid nutritional supplement produced by the Catalysis Laboratories of Spain. Patients will receive oral treatment throughout the onco-specific treatment and up to 3 weeks after completion.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Carcinoma Stage II | Cervical Carcinoma | CURATED_BROADER | 0.78 |
| Cervical Carcinoma Stage III | Cervical Carcinoma | CURATED_BROADER | 0.78 |
| Cervical Carcinoma Stage IV | Cervical Carcinoma | CURATED_BROADER | 0.78 |
| Endometrial Adenocarcinoma Stage II | Endometrial Adenocarcinoma | CURATED_BROADER | 0.80 |
| Endometrial Adenocarcinoma Stage III | Endometrial Adenocarcinoma | CURATED_BROADER | 0.80 |
| Endometrial Adenocarcinoma Stage IV | Endometrial Adenocarcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oncoxin-Viusid® | Dietary Supplement | — | UNRESOLVED |
| Placebo | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Oncoxin-Viusid®
- description
- will receive the Oncoxin-Viusid® (oral solution) concomitant to the onco-specific treatment.
- interventionNames
- Dietary Supplement: Oncoxin-Viusid®
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- will receive a Placebo concomitant to the onco-specific treatment
- interventionNames
- Dietary Supplement: Placebo
Primary outcomes (1)
- measure
- Toxicity of chemotherapy and radiotherapy in patients diagnosed with cervical cancer and endometrium adenocarcinoma.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histological confirmation of cervical cancer and adenocarcinoma of the endometrium that are treated with chemotherapy and ionizing radiation. * Patient with age equal to or greater than 18 years and up to 80 years. * Patients who do not present decompensated concurrent diseases at the time of diagnosis that prevent or contraindicate the application of treatment with chemo-radiotherapy. * Informed consent to participate in the investigation. * Patients with an ECOG \<or equal to 3. Exclusion Criteria: * Patients with a history of renal failure that contraindicates the administration of cisplatin. * Concomitant diseases unbalanced at the time of diagnosis or during the application of treatment. * Patients with an ECOG\> 3. * Pregnant or lactating women. * Patients who are receiving another research product. * Patients who do not show consent to participate in the study.
References
Publications (0)
Data not yet available